KGK Science at PS2023
August 10th, 2022
Today, Psychedelic Science 2023, hosted by Multidisciplinary Association for Psychedelic Studies (MAPS) and organized by Momentum Events, announced that KGK Science has joined the event as the first Founding Sponsor.
With an estimated 10,000 attendees, Psychedelic Science 2023 will be the world’s largest gathering of the psychedelic ecosystem, taking place June 17-25, 2023 in Denver, Colorado and will feature three days of panels, workshops, and lectures from leaders and visionaries from psychedelic research, education, policy, business, culture, and communities. Conference tracks will be complemented by pre- and post-conference workshops; an exhibit hall; and a marketplace featuring artists, musicians, and other vendors from around the world.
“Wellbeing Digital, and its subsidiary KGK Science, are thrilled to be sponsoring and presenting at this remarkable event and we applaud this great initiative MAPS has undertaken to bring the industry together under one roof to make this gathering one not to miss,” stated Najla Guthrie, CEO, Wellbeing Digital Sciences. “Psychedelic Science 2023 is especially timely for Wellbeing as we are focused on building out our already established clinical network, working with partners to propel psychedelic research forward and investing in digital therapeutics. It is truly a privilege and honour to be working with MAPS and other Sponsors to propel the industry forward and bring these promising treatments to a patient base in dyer need,” concluded Ms. Guthrie.
Attendees will include MAPS members, donors, researchers, students, clinicians, advocates, therapists, political leaders, entrepreneurs, executives, investors, psychedelic enthusiasts, and those who may benefit from MAPS’ decades of research and advocacy.
About Wellbeing Digital Science
Wellbeing Digital Sciences Inc. is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical treatment solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research. Its mission is supported by a network of North American clinics that provide forward-thinking therapies and other types of treatment to patients as well as through a contract research organization that offers clinical trials services to clients pursuing drug development. For additional information, please visit wellbeingdigital.co.
ABOUT KGK SCIENCE
Subsidiary of Wellbeing Digital Sciences, KGK is a leading North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on nutraceutical and emerging health care products. Founded in 1997, the business has successfully helped hundreds of companies with custom designed clinical trials and claim substantiation strategies to move products into global markets. KGK’s other existing service lines include expert regulatory support and compliance solutions, participant recruitment, research support services and consulting services. Furthermore, the company has produced over 150 publications, executed over 400 clinical trials across more than 40 indications, amassed 25,000 participants in its database and collected 10 million data points. For additional information, please visit kgkscience.com.
For further information, please contact:
VP of Marketing & Investment Relations
About Momentum Events
Founded in 2012, Momentum Events proudly serves our clients and produces events that attract the best and brightest minds who come together to share their knowledge, connect with the individuals that matter most and enjoy valuable experiences online or in real life. Whether we’re developing cutting edge conferences for the markets we serve, or producing a partner’s next event, Momentum leverages our best in class technology platforms, an assortment of virtual and live event third-party provider relationships, and the meticulous nature of our event planning mindset to deliver true, sustainable value for all stakeholders. www.momentumevents.com
Founded in 1986, MAPS is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS is sponsoring the most advanced psychedelic therapy research in the world: Phase 3 clinical trials of MDMA-assisted therapy for PTSD. Since its founding, MAPS has raised over $130 million for psychedelic and marijuana research and education and has earned both the Guidestar Platinum Seal of Transparency and a 4-Star Rating from Charity Navigator.